UK
UK
Jul-10
Endocrinology Pharmacoepidemiology
Read moreOct-09
Endocrinology Oncology Pharmacoepidemiology
Read moreSep-09
Endocrinology Oncology Pharmacoepidemiology
Read moreAug-09
Endocrinology Pharmacoepidemiology
Read moreJun-09
Endocrinology Gastroenterology Respiratory
Read moreFeb-09
Endocrinology Pharmacoepidemiology
Read moreJan-09
Nov-08
Endocrinology Healthcare Cost Pharmacoepidemiology
Read moreNov-08
Endocrinology Healthcare Cost Pharmacoepidemiology
Read moreNov-08
Endocrinology Healthcare Cost Pharmacoepidemiology
Read moreNov-08
Endocrinology Pharmacoepidemiology
Read more| Date | Title | Categories | |
|---|---|---|---|
| Jul-10 | Insulin usage in type 2 diabetes mellitus patients in UK clinical practice: a retrospective cohort-based analysis using the THIN database | Read more | |
| Oct-09 | Insulin, metformin and cancer risk in type 2 diabetes | Read more | |
| Sep-09 | The influence of glucose-lowering therapies on cancer risk in type 2 diabetes | Read more | |
| Aug-09 | Effect of Angiotensin Receptor Blockers and Angiotensin Converting Enzyme Inhibitors on Limb Amputation | Read more | |
| Jun-09 | Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis | Read more | |
| Apr-09 | Trends in the prevalence and incidence of diabetes in the UK: 1996-2005 | Read more | |
| Feb-09 | Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis | Read more | |
| Jan-09 | The clinical impact of identifying metabolic syndrome in patients with diabetes: a cross-sectional study | Read more | |
| Nov-08 | Is Insulin Glargine a Cost-Effective Option for Treatment of Patients Naive to Insulin Treatment with Type 2, Baseline HBA1C Above 8% and Age Below 65 Years in Comparison to NPH and Premix in Poland? | Read more | |
| Nov-08 | Is Insulin Glargine a Cost Effective Option in Treatment of Patients with Type DM1 with Baseline HBA1C Above 8% in Comparison to NPH and Premix in Poland? | Read more | |
| Nov-08 | Cost-Utility of Insulin Glargine Compared to Pre Mix in Type 2 from Public Payer Perspective in Poland | Read more | |
| Nov-08 | Improved Glycaemic Control by Switching from Insulin NPH to Insulin Glargine: a Retrospective Observational Study | Read more |
